FDA Inspection 1059413 — GlaxoSmithKline Consumer Private Limited
The FDA completed an inspection of GlaxoSmithKline Consumer Private Limited on May 30, 2018 in Hyderabad. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 30, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Hyderabad (India)